Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30024104HIVENSG00000116783.15protein_codingTNNI3KNoNo51086Q59H18
TVIS20047591HPVENSG00000116783.15protein_codingTNNI3KNoNo51086Q59H18
TVIS20016673HPVENSG00000116783.15protein_codingTNNI3KNoNo51086Q59H18
TVIS20044857HPVENSG00000116783.15protein_codingTNNI3KNoNo51086Q59H18
TVIS20042922HPVENSG00000116783.15protein_codingTNNI3KNoNo51086Q59H18
TVIS20034009HPVENSG00000116783.15protein_codingTNNI3KNoNo51086Q59H18
TVIS44002818HTLV-1ENSG00000116783.15protein_codingTNNI3KNoNo51086Q59H18
TVIS44024614HTLV-1ENSG00000116783.15protein_codingTNNI3KNoNo51086Q59H18
TVIS44018701HTLV-1ENSG00000116783.15protein_codingTNNI3KNoNo51086Q59H18
TVIS44048680HTLV-1ENSG00000116783.15protein_codingTNNI3KNoNo51086Q59H18
TCGA Plot Options
Drug Information
GeneTNNI3K
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009401
UniProt IDQ59H18
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830